Heart Failure with Reduced, Mildly Reduced, or Preserved Left Ventricular Ejection Fraction: Has Reasoning Been Lost?

Overview

Journal World J Cardiol

Publisher Baishideng Publishing Group

Specialty Cardiology & Vascular Diseases

Date 2022 Sep 26

PMID 36161058

Authors

Andrew Xanthopoulos

Grigorios Giamouzis

John Skoularigis

Filippos Triposkiadis

Affiliations

Soon will be listed here.

Abstract

Left ventricular (LV) ejection fraction (LVEF), defined as LV stroke volume divided by end-diastolic volume, has been systematically used for the diagnosis, classification, and management of heart failure (HF) over the last three decades. HF is classified as HF with reduced LVEF, HF with midrange or mildly reduced LVEF, and HF with preserved LVEF using arbitrary, continuously changing LVEF cutoffs. A prerequisite for using this LVEF-based terminology is knowledge of the LVEF normal range, which is lacking and may lead to erroneous conclusions in HF, especially at the higher end of the LVEF spectrum.

Citing Articles

Diagnostic and therapeutic practice for HFpEF across continents and regions: An international survey.

Ingimarsdottir I, Vishram-Nielsen J, Einarsson H, Goldfeder S, Mewton N, Barasa A ESC Heart Fail. 2024; 12(1):487-496.

PMID: 39351634 PMC: 11769610. DOI: 10.1002/ehf2.15084.

Machine learning in heart failure diagnosis, prediction, and prognosis: review.

Saqib M, Perswani P, Muneem A, Mumtaz H, Neha F, Ali S Ann Med Surg (Lond). 2024; 86(6):3615-3623.

PMID: 38846887 PMC: 11152866. DOI: 10.1097/MS9.0000000000002138.

A case report of a patient with heart failure with preserved ejection fraction presented as dysphagia.

Leonidou E, Ioannou M, Mavrommatis P, Mouzarou A ESC Heart Fail. 2023; 10(4):2707-2710.

PMID: 37254634 PMC: 10375080. DOI: 10.1002/ehf2.14415.

Heart failure outcomes in low-risk patients with atrial fibrillation: a case-control study of 680 523 Swedish individuals.

Basic C, Hansson P, Sandstrom T, Johansson B, Fu M, Mandalenakis Z ESC Heart Fail. 2023; 10(4):2281-2289.

PMID: 37139589 PMC: 10375091. DOI: 10.1002/ehf2.14375.

The Neurohormonal Overactivity Syndrome in Heart Failure.

Xanthopoulos A, Skoularigis J, Triposkiadis F Life (Basel). 2023; 13(1).

PMID: 36676199 PMC: 9864042. DOI: 10.3390/life13010250.

References

Pitt B, Pfeffer M, Assmann S, Boineau R, Anand I, Claggett B . Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370(15):1383-92. DOI: 10.1056/NEJMoa1313731. View

Pieske B, Maggioni A, Lam C, Pieske-Kraigher E, Filippatos G, Butler J . Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017; 38(15):1119-1127. PMC: 5400074. DOI: 10.1093/eurheartj/ehw593. View

Cleland J, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J . The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006; 27(19):2338-45. DOI: 10.1093/eurheartj/ehl250. View

Smiseth O, Aalen J, Skulstad H . Heart failure and systolic function: time to leave diagnostics based on ejection fraction?. Eur Heart J. 2021; 42(7):786-788. PMC: 7882370. DOI: 10.1093/eurheartj/ehaa979. View

Stewart S, Playford D, Scalia G, Currie P, Celermajer D, Prior D . Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men. Eur J Heart Fail. 2020; 23(3):406-416. DOI: 10.1002/ejhf.2047. View

Van Veldhuisen D, Cohen-Solal A, Bohm M, Anker S, Babalis D, Roughton M . Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart.... J Am Coll Cardiol. 2009; 53(23):2150-8. DOI: 10.1016/j.jacc.2009.02.046. View

Harkness A, Ring L, Augustine D, Oxborough D, Robinson S, Sharma V . Normal reference intervals for cardiac dimensions and function for use in echocardiographic practice: a guideline from the British Society of Echocardiography. Echo Res Pract. 2020; 7(1):X1. PMC: 8117370. DOI: 10.1530/ERP-19-0050. View

Armstrong P, Lam C, Anstrom K, Ezekowitz J, Hernandez A, OConnor C . Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. JAMA. 2020; 324(15):1512-1521. PMC: 7576403. DOI: 10.1001/jama.2020.15922. View

Massie B, Carson P, McMurray J, Komajda M, McKelvie R, Zile M . Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008; 359(23):2456-67. DOI: 10.1056/NEJMoa0805450. View

10.

Hudson S, Pettit S . What is 'normal' left ventricular ejection fraction?. Heart. 2020; 106(18):1445-1446. DOI: 10.1136/heartjnl-2020-317604. View

11.

Carrasco-Ruiz M, Ruiz-Rivera A, Soriano-Ursua M, Martinez-Hernandez C, Manuel-Apolinar L, Castillo-Hernandez C . Global longitudinal strain is superior to ejection fraction for detecting myocardial dysfunction in end-stage renal disease with hyperparathyroidism. World J Cardiol. 2022; 14(4):239-249. PMC: 9048274. DOI: 10.4330/wjc.v14.i4.239. View

12.

Ahmed A, Rich M, Fleg J, Zile M, Young J, Kitzman D . Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006; 114(5):397-403. PMC: 2628473. DOI: 10.1161/CIRCULATIONAHA.106.628347. View

13.

Henning R . Diagnosis and treatment of heart failure with preserved left ventricular ejection fraction. World J Cardiol. 2020; 12(1):7-25. PMC: 6952725. DOI: 10.4330/wjc.v12.i1.7. View

14.

Redfield M, Chen H, Borlaug B, Semigran M, Lee K, Lewis G . Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013; 309(12):1268-77. PMC: 3835156. DOI: 10.1001/jama.2013.2024. View

15.

Yancy C, Lopatin M, Stevenson L, De Marco T, Fonarow G . Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006; 47(1):76-84. DOI: 10.1016/j.jacc.2005.09.022. View

16.

Yamamoto K, Origasa H, Hori M . Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2012; 15(1):110-8. DOI: 10.1093/eurjhf/hfs141. View

17.

Zheng S, Chan F, Nabeebaccus A, Shah A, McDonagh T, Okonko D . Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 2017; 104(5):407-415. PMC: 5861385. DOI: 10.1136/heartjnl-2017-311652. View

18.

Gebhard C, Maredziak M, Messerli M, Buechel R, Lin F, Gransar H . Increased long-term mortality in women with high left ventricular ejection fraction: data from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter) long-term registry. Eur Heart J Cardiovasc Imaging. 2020; 21(4):363-374. PMC: 7778362. DOI: 10.1093/ehjci/jez321. View

19.

Ioannidis J . Why most published research findings are false. PLoS Med. 2005; 2(8):e124. PMC: 1182327. DOI: 10.1371/journal.pmed.0020124. View

20.

Solomon S, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E . The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012; 380(9851):1387-95. DOI: 10.1016/S0140-6736(12)61227-6. View